Oragenics (OGEN)
(Delayed Data from AMEX)
$1.62 USD
-0.02 (-1.22%)
Updated Jun 17, 2024 03:59 PM ET
After-Market: $1.65 +0.03 (1.85%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Oragenics, Inc. [OGEN]
Reports for Purchase
Showing records 21 - 39 ( 39 total )
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Strengthened Balance Sheet Should Allow Company to Reach Key Inflection Points
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Roller Coaster Ride, but Risk-Reward Still Favorable for Underlying Business
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Roller Coaster Ride, but Risk-Reward Still Favorable for Underlying Business
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Financing Proceeds Should Allow Company to Reach Key Trial Inflection Points
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of Coverage - Leveraging Probiotic and Antibiotic Research to Serve a Large Global Market
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
We are suspending coverage with this report as part of a reallocation of our resources
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Oragenics has begun a process of rebuilding itself
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Diversified R&D Portfolio Augurs Well for Long-Term Prospects
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Diversified R&D Portfolio Augers Well for Long-Term Prospects
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
MAJOR LANTIBIOTIC MILESTONE IS ACHIEVED WITH INTREXON
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a BUY recommendation and $5.00 price target
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K